

Anti-Parkinsonian. It has a central m-anticholinergic effect, inhibits enhanced inhibitory function of cholinergic striatal neurons (the structural component of the extrapyramidal system). It also has a moderate peripheral m-anticholinergic effect, myotropic antispasmodic and ganglion blocker effect. Causes psychomotor agitation.
Parkinson's disease, parkinsonism syndrome (as part of combination therapy), extrapyramidal disorders caused by antipsychotics (neuroleptics).
1 tab. - Biperidine hydrochloride 2 mg.
Excipients: microcrystalline cellulose - 192 mg, sodium carboxymethyl starch - 5 mg, magnesium stearate - 1 mg.
Biperiden is marketed under different brands and generic names, and comes in different dosage forms:
Brand name | Manufacturer | Country | Dosage form |
---|---|---|---|
Bezac | pills | ||
pills |
No customer reviews for the moment.
Bezak is taken orally with a liquid. The drug is preferable to take at the same time / after a meal (reduces the severity of adverse reactions from the digestive system). The recommended scheme of application: parkinsonism syndrome: the initial dose - 1–2 times a day, 1 mg. Daily dose can be increased by 2 mg. Maintenance daily dose is 3-16 mg. Maximum - 16 mg per day. The total daily dose needs to be distributed evenly throughout the day; extrapyramidal symptoms (as a neuroleptic treatment corrector): the initial dose is determined by the severity of the symptoms and is 1-2 mg 1-4 times a day. A single dose can be increased to 4 mg, daily - up to 16 mg. The duration of the course is determined individually, it depends on the etiology and severity of the disease. After the end of the course, the dose should be reduced gradually (due to the high risk of abstinence).
From the side of the central nervous system: weakness, asthenia, dizziness, numbness, anxiety, impaired memory, confusion, hallucinations.
On the part of the organ of vision: mydriasis, disturbance of accommodation.
Since the cardiovascular system: tachycardia; rarely bradycardia; with parenteral administration - a decrease in blood pressure.
On the part of the digestive system: dry mouth, dyspepsia, constipation.
On the part of metabolism: a decrease in sweating.
On the part of the urinary system: in patients with prostatic hypertrophy - difficulty urinating.
Allergic reactions: skin rash, itching.
Angle-closure glaucoma, prostatic hyperplasia, obstructive conditions of the gastrointestinal tract (including pyloric stenosis, paralytic intestinal obstruction), megacolon; hypersensitivity to biperiden.
With simultaneous use with anticholinergic drugs may enhance the central and peripheral anticholinergic effects.
With simultaneous use with antipsychotics (neuroleptics) increases the risk of tardive dyskinesia.
With simultaneous use with biperiden, the effect of histamine H1 receptor blockers and anticonvulsants increases.
At simultaneous use with a levodopa strengthening of the m-anticholinergic action and dyskinesia is possible.
With simultaneous use of biperiden reduces the effectiveness of metoclopramide.
With simultaneous use with quinidine increases the risk of dyskinesia. Potentiates the action of ethanol.
The use of biperidine during pregnancy and lactation (breastfeeding) is possible only under strict indications. Biperiden is excreted in breast milk, so for the period of treatment, breastfeeding is recommended to stop.
It is used with caution in patients with epilepsy, arrhythmia, in elderly patients.
Perhaps the development of drug dependence.
Treatment should be discontinued gradually because of the risk of withdrawal.
The safety of using biperidine in children has not been established, so the use is not recommended.
During the period of treatment to prevent the use of alcohol.
Influence on ability to drive motor transport and control mechanisms
Use with caution in patients whose activities require increased attention and speed of psychomotor reactions.
Studies and clinical trials of Biperiden (Click to expand)